Detalhe da pesquisa
1.
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(7): 916-929, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908991
2.
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(6): 822-835, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132212
3.
A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
Vaccine
; 39(43): 6398-6406, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593270
4.
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.
Vaccine
; 38(7): 1678-1689, 2020 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932137
5.
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 26(7): 1725-1735, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732522
6.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 20(6): 719-730, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199492
7.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 20(6): 707-718, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199491
8.
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.
NPJ Vaccines
; 4: 51, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31839997
9.
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
J Clin Oncol
; 23(36): 9250-6, 2005 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16361622
10.
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.
J Thorac Oncol
; 11(12): 2208-2217, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27544054
11.
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
J Thorac Oncol
; 10(10): 1458-67, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26309191
12.
Adjusted significance levels for subgroup analyses in clinical trials.
Contemp Clin Trials
; 31(6): 647-56, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20832503
13.
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Eur Urol
; 53(5): 941-9, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18191322
14.
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.
Ann Surg
; 246(5): 734-40, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17968163
15.
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
J Clin Oncol
; 25(18): 2580-5, 2007 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17577037
16.
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
J Clin Oncol
; 24(12): 1868-76, 2006 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16622261
17.
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Lancet Oncol
; 6(7): 459-68, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15992694
18.
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
J Urol
; 172(3): 923-7, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15310999
19.
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Eur Urol
; 45(4): 457-64, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15041109